LOGIN  |  REGISTER
Amneal Pharmaceuticals
Amneal Pharmaceuticals

InMode to Present at Upcoming Investor Conferences and Events

November 06, 2023 | Last Trade: US$14.66 0.07 0.48

YOKNEAM, Israel, Nov. 6, 2023 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences and events in November and December:

Jefferies London Healthcare Conference
Presenters: Moshe Mizrahy, Chief Executive Officer and Chairman
Format: In-person fireside chat moderated by Matt Taylor, Senior Equity Analyst, and one-on-one meetings
Location: London, U.K.
When: Tuesday, Nov. 14 at 8:00 am GMT
A live webcast of the presentation can be accessed here.

Canaccord MTDF Investor Conference
Presenters: Yair Malca, Chief Financial Officer
Format: In-person one-on-one meetings
Location: New York, NY
When: Thursday, Nov. 16

Mizuho Medical Device and Healthcare Services Summit 2023
Presenters: Yair Malca, Chief Financial Officer
Format: In-person one-on-one meetings
Location: New York, NY
When: Wednesday, Dec. 6

About InMode

InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com

Investor Relations Contact:
Miri Segal-Scharia
MS-IR LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
917-607-8654

Astria Therapeutics

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page